Annexon (NASDAQ:ANNX) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to outline a set of ...

Sensorineural hearing loss (SNHL) is a highly prevalent sensory disorder globally, affecting over 1.5 billion people, with a ...

The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...

Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...

In the wake of the National Guard shooting, the Trump administration has temporarily frozen major pathways for many migrants to obtain legal status in the United States. By Madeleine Ngo Reporting ...

ATLANTA — Residents in a Buckhead senior community said they've endured two sleepless nights due to loud classical music and flashing blue lights coming from a mobile surveillance system installed in ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...

Lots of people are excited about the idea of using plants to help us draw down some of the excess carbon dioxide we’ve been pumping into the atmosphere. It would be nice to think that we could ...

Among people with sickle cell disease—an inherited blood disorder—acute chest syndrome (ACS) is the leading cause of death. The condition is the result of red blood cells becoming stiff, sticky, and ...

ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...